Last A$0.03 AUD
Change Today -0.001 / -3.70%
Volume 699.7K
As of 1:58 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

cellmid ltd (CDY) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/20/13 - A$0.05
52 Week Low
04/16/14 - A$0.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLMID LTD (CDY)

Related News

No related news articles were found.

cellmid ltd (CDY) Related Businessweek News

No Related Businessweek News Found

cellmid ltd (CDY) Details

Cellmid Limited, a biotechnology company, is engaged in the development and commercialization of diagnostic and therapeutic products for heart attack, inflammatory diseases, and cancer in Australia. It offers MK ELISA, a sandwich enzyme immunoassay in a 96 well plate format for measuring MK levels in human serum samples. The company’s pipeline diagnostic programs include CAN104, a canine cancer diagnostic product, as well as CS5000 and CK3000, the cancer screening products; and CAMI103, a therapeutic program for heart attack, as well as CAB101, an anti-inflammatory antibody. It also develops and sells FGF-5, an over-the-counter treatment to alleviate excessive and abnormal hair loss and re-establish the natural hair growth cycle; and Évolis, a hair growth tonic for men and women. Cellmid Limited is based in Sydney, Australia.

cellmid ltd (CDY) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$400.0K
Financial Controller and Company Secretary
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

cellmid ltd (CDY) Key Developments

Cellmid Limited Presents at 2014 Asia Biotech Invest Conference, Jun-05-2014 03:00 PM

Cellmid Limited Presents at 2014 Asia Biotech Invest Conference, Jun-05-2014 03:00 PM. Venue: Sheraton Hong Kong Hotel & Towers, 20 Nathan Road, Kowloon, Hong Kong. Speakers: Maria Halasz, Chief Executive Officer, Managing Director and Executive Director.

Cellmid Limited Reports Consolidated Earnings Results for the Six Months Ended December 31, 2013

Cellmid Limited reported consolidated earnings results for the six months ended December 31, 2013. For the period, the company reported revenue of AUD 1,529,074 compared to AUD 258,200 a year ago. Loss before income tax was AUD 475,479 compared to AUD 1,178,942 a year ago. Loss for the half-year attributable to the company was AUD 242,029 or 0.04 cent basic and diluted per share compared to AUD 389,430 or 0.09 cent basic and diluted per share a year ago. Net cash used by operating activities was AUD 687,546 compared to AUD 218,399 a year ago.

Cellmid Limited Signs Chinese Distribution Agreement with Beijing Huana Likang Biotechnology Co. Ltd

Cellmid Limited announced that it has signed a Chinese distribution agreement for its Lexilis Black and Jo-Ju brands with Beijing Huana Likang Biotechnology Co. Ltd. The distribution agreement is exclusive for these brands in China subject to minimum performance requirements. The agreement is for a period of three years, however it may be automatically extended if minimum sales are met.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDY:AU A$0.03 AUD -0.001

CDY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CDY.
View Industry Companies

Industry Analysis


Industry Average

Valuation CDY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.9x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLMID LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at